[go: up one dir, main page]

JPH06105906A - Dialysis agent - Google Patents

Dialysis agent

Info

Publication number
JPH06105906A
JPH06105906A JP3107044A JP10704491A JPH06105906A JP H06105906 A JPH06105906 A JP H06105906A JP 3107044 A JP3107044 A JP 3107044A JP 10704491 A JP10704491 A JP 10704491A JP H06105906 A JPH06105906 A JP H06105906A
Authority
JP
Japan
Prior art keywords
agent
glucose
dialysis
dialysate
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3107044A
Other languages
Japanese (ja)
Inventor
Nobuo Ito
信夫 伊藤
Shigeru Maeyama
茂 前山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikkiso Co Ltd
Towa Pharmaceutical Co Ltd
Original Assignee
Nikkiso Co Ltd
Towa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikkiso Co Ltd, Towa Pharmaceutical Co Ltd filed Critical Nikkiso Co Ltd
Priority to JP3107044A priority Critical patent/JPH06105906A/en
Publication of JPH06105906A publication Critical patent/JPH06105906A/en
Pending legal-status Critical Current

Links

Landscapes

  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide the agent for dialysis which is in a powdery form advantageous for storage and transportation and does not discolor even after long-term preservation. CONSTITUTION:This agent for dialysis is prepd. by mixing a solid electrolyte and glucose component and the moisture in such mixture is <=2.0wt.%. sodium bicarbonate is used as an alkalinizer.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、透析液を製造するため
の透析用剤に関するものである。
TECHNICAL FIELD The present invention relates to a dialysis agent for producing a dialysate.

【0002】[0002]

【従来の技術】透析用剤は、透析液を作製するための薬
剤である。透析液は、人工腎臓、血液透析、腹膜透析な
どにより本来腎臓が行う機能に代わり、体液の老廃物を
取り去り、更には血液中に必要な成分を補うために用い
るものである。透析液として、アルカリ化剤として酢酸
ナトリウムを用いる酢酸透析液と、アルカリ化剤として
重曹を用いる重曹透析液の2種が知られている。
2. Description of the Related Art A dialysis agent is a drug for producing a dialysate. The dialysate replaces the function originally performed by the kidney by artificial kidney, hemodialysis, peritoneal dialysis, etc., and is used for removing waste products of body fluid and for supplementing necessary components in blood. Two types of dialysate are known, an acetic acid dialysate using sodium acetate as an alkalizing agent and a baking soda dialysate using sodium bicarbonate as an alkalizing agent.

【0003】例えば、重曹透析液は、以下に示すような
電解質イオン組成を有するものが用いられている。 Na+ 120〜150 mEq/l K+ 0.5〜3.0 mEq/l Ca++ 1.5〜4.5 mEq/l Mg++ 0〜2.0 mEq/l Cl- 90〜135 mEq/l CH3COO- 5〜 35 mEq/l HCO3 - 20〜 35 mEq/l ブドウ糖 0〜2.5 g/l
For example, a baking soda dialysate having an electrolyte ion composition as shown below is used. Na + 120 to 150 mEq / l K + 0.5 to 3.0 mEq / l Ca ++ 1.5 to 4.5 mEq / l Mg ++ 0 to 2.0 mEq / l Cl - 90 to 135 mEq / l CH 3 COO - 5 to 35 mEq / l HCO 3 - 20~ 35 mEq / l of glucose 0~2.5 g / l

【0004】普通、重曹透析液は、重曹以外の必要電解
質及びブドウ糖成分の濃厚溶液とアルカリ化剤としての
重曹水溶液とに分け、透析時に両者を混合希釈して用い
られる。重曹については粉末状にて保存あるいは輸送し
て使用の直前に溶解することもある。
Usually, a sodium bicarbonate dialysate is divided into a concentrated solution of necessary electrolytes and glucose components other than sodium bicarbonate and an aqueous sodium bicarbonate solution as an alkalizing agent, and both are mixed and diluted during dialysis. Baking soda may be stored or transported in powder form and dissolved immediately before use.

【0005】しかしながら、前記のように電解質及びブ
ドウ糖成分の溶液を予め調製しておく場合には、これを
濃厚な原液としたにしても、かなりの容積と重量にな
り、貯留や運搬や使用時の取扱に不便である。この欠点
を避けるため、電解質及びブドウ糖成分を粉体として貯
留や運搬を行う透析用剤も知られている。
However, in the case where the solution of the electrolyte and glucose component is prepared in advance as described above, even if this solution is made into a concentrated stock solution, the volume and weight become considerable, and the solution is stored, transported or used. Is inconvenient to handle. In order to avoid this drawback, a dialysis agent that stores and transports the electrolyte and glucose components as powder is also known.

【0006】酢酸透析用剤としては、重曹透析用剤と同
様の電解質及びブドウ糖成分に、直接アルカリ化剤とし
ての酢酸ナトリウムを粉末で加えた粉体状のものが知ら
れている。
As the acetic acid dialysis agent, there is known a powdery one in which sodium acetate as a direct alkalizing agent is added as a powder to the same electrolyte and glucose components as the sodium bicarbonate dialysis agent.

【0007】[0007]

【発明が解決しようとする課題】しかしブドウ糖を含む
粉体を長期間保存していると、ブドウ糖が変質し黄色に
着色する現象(以下黄色化という)が発生する。黄色化
は、透析液の生理的効果には、直接悪影響を及ぼすもの
ではないが、透析用剤の外観が黄色を呈するので、商品
価値を低下させる。
However, when the powder containing glucose is stored for a long period of time, a phenomenon in which glucose is deteriorated and colored yellow (hereinafter referred to as yellowing) occurs. Yellowing does not directly adversely affect the physiological effect of the dialysate, but the appearance of the dialysate exhibits a yellow color, which reduces the commercial value.

【0008】[0008]

【課題を解決するための手段】本発明者は、ブドウ糖の
黄色化に影響を及ぼす要因について詳細な検討を行い、
透析用剤中の水分の量を特定の範囲にすることにより黄
色化を抑制できることを見いだしたものである。
Means for Solving the Problems The present inventor has conducted a detailed study on factors affecting the yellowing of glucose,
It was found that yellowing can be suppressed by controlling the amount of water in the dialysate to a specific range.

【0009】本発明は、固体の電解質及びブドウ糖成分
を混合した透析用剤において、この混合物中の水分が2.
0 重量%以下である透析用剤を提供するものである。
The present invention relates to a dialysis agent in which a solid electrolyte and a glucose component are mixed, and the water content in the mixture is 2.
A dialysis agent having a content of 0% by weight or less is provided.

【0010】本発明においては、各電解質成分およびブ
ドウ糖(以下A剤という。)中の水分を2.0 重量%以下
に、 好ましくは1.8 重量%以下、さらに好ましくは1.3
重量%以下にすることにより、A剤の黄色化の進行を限
度内に抑制できる。透析剤中の水分は、例えば、日本薬
局方のカールフィッシャー法などで測定することができ
る。
In the present invention, the water content in each electrolyte component and glucose (hereinafter referred to as agent A) is 2.0% by weight or less, preferably 1.8% by weight or less, more preferably 1.3% by weight or less.
When the content is less than or equal to wt%, the progress of yellowing of the agent A can be suppressed within the limit. The water content in the dialysate can be measured, for example, by the Karl Fischer method of the Japanese Pharmacopoeia.

【0011】ここで、電解質成分としては、慣用のもの
を用いることができ、例えばNaCl、KCl、CaC
2 、MgCl2 、酢酸ナトリウムなどの塩類、乳酸、
酢酸、塩酸などの酸類(pH調整剤)を用いる。
Here, as the electrolyte component, a conventional one can be used, for example, NaCl, KCl, CaC.
l 2 , MgCl 2 , salts such as sodium acetate, lactic acid,
Acids (pH adjusters) such as acetic acid and hydrochloric acid are used.

【0012】本発明においてA剤が造粒されている場合
は、流動性が向上し発塵の抑制ができるので好ましい。
造粒物の細孔容積は0.03〜0.2 cc/gであることが好まし
い。細孔容積が0.03cc/gに満たない場合は、溶解速度が
遅くなる恐れがあるので好ましくない。細孔容積が0.2
cc/gを超える場合は、造粒物の強度が低下して発塵性が
現れる可能性があるので好ましくない。
In the present invention, the case where the agent A is granulated is preferable because the fluidity is improved and the generation of dust can be suppressed.
The pore volume of the granulated product is preferably 0.03 to 0.2 cc / g. If the pore volume is less than 0.03 cc / g, the dissolution rate may slow down, which is not preferable. Pore volume is 0.2
If it exceeds cc / g, the strength of the granulated product may decrease and dust generation may appear, which is not preferable.

【0013】A剤を造粒する場合は、各成分を粉体のま
ま適宜水と共に混合し、種々の造粒機を用いて造粒する
ことができる。電解質成分粉末を粒度調製し、水分が1
〜25重量%となるように水を加えて充分混合し、押し出
し造粒機等により造粒後、乾燥することにより、顆粒状
の製品とする。造粒に際し水分が1重量%に満たない場
合には、粒子強度が低くなるため粉化し昜くなり、逆に
25重量%を越える場合には造粒が困難となる恐れがある
ので何れも好ましくない。
In the case of granulating the agent A, the respective components can be appropriately mixed in the form of powder with water and granulated using various granulators. The particle size of the electrolyte component powder is adjusted so that the water content is 1
Water is added to -25% by weight, mixed well, granulated by an extrusion granulator or the like, and dried to give a granular product. If the water content during granulation is less than 1% by weight, the particle strength will decrease and the powder will be pulverized and vice versa.
If it exceeds 25% by weight, granulation may be difficult, and therefore neither is preferable.

【0014】用いられる原料としての電解質及びブドウ
糖成分の粉末の粒子径としては250μm以下、好ましく
は180 μm以下、更に好ましくは100 μm以下を採用す
るのが適当である。粒子径が250 μmを越える場合に
は、最終品となる顆粒の機械的強度が不充分となり、粉
化し昜くなり、また溶解速度が遅くなるので好ましくな
い。
It is suitable that the particle size of the powder of the electrolyte and glucose component used as the raw materials used is 250 μm or less, preferably 180 μm or less, more preferably 100 μm or less. If the particle size exceeds 250 μm, the mechanical strength of the final granules becomes insufficient, and the granules become pulverized and deteriorate, and the dissolution rate becomes slow, which is not preferable.

【0015】造粒される粒子の粒径は0.1 〜10mm程度に
するのが適当である。粒状体の粒径が前記範囲に満たな
い場合には流動性が阻害されたり、粉化して飛散したり
して取扱が困難となり、逆に前記範囲を越える場合には
粒子の機械的強度が低下したり、溶解に時間がかかりす
ぎたりする恐れがあるので何れも好ましくない。
The particle size of the granulated particles is preferably about 0.1 to 10 mm. If the particle size of the granules is less than the above range, the fluidity is impaired, or the particles become scattered and scattered, making it difficult to handle. Conversely, if the particle size exceeds the above range, the mechanical strength of the particles decreases. Both of them are not preferable because they may occur or the dissolution may take too long.

【0016】造粒物の乾燥の際には、かつ乾燥中の加熱
によりブドウ糖の黄色化の進行を防止するために乾燥を
より低い温度条件で行うことが望ましい。したがって、
脱湿した後加熱された空気を用いるのが好ましい。乾燥
は、30〜90℃において行うのが適当であり、具体的乾燥
手段としては例えば、バンド乾燥機、円板乾燥機、通気
乾燥機、回転乾燥機等を採用することにより、高強度及
び易溶性で均一かつ組成安定の良好な顆粒を得ることが
可能となる。
When drying the granulated product, it is desirable to carry out the drying under a lower temperature condition in order to prevent the progress of the yellowing of glucose due to the heating during the drying. Therefore,
It is preferable to use heated air after dehumidification. It is appropriate to carry out drying at 30 to 90 ° C. As a specific drying means, for example, a band dryer, a disk dryer, an aeration dryer, a rotary dryer, etc. can be used to obtain high strength and easy drying. It is possible to obtain granules that are soluble, uniform, and have a stable composition.

【0017】本発明の透析用剤においては、溶解したあ
とのpHを調整する目的で予め酢酸のようなpH調整成分を
含むものであってもよい。pH調整成分は溶解後の透析液
に加えてもよい。
The dialysis agent of the present invention may contain a pH adjusting component such as acetic acid in advance for the purpose of adjusting the pH after dissolution. The pH adjusting component may be added to the dialysate after dissolution.

【0018】本発明を、重曹透析用剤に適用する場合、
アルカリ化剤としての重曹成分(以下B剤という。)
は、特に限定されるものではなく、濃厚溶液で供給され
るものでも粉体で供給されるものでもよい。粉体で供給
される場合は、B剤も造粒されていることが、流動性が
向上し、発塵を押えることができるので好ましい。
When the present invention is applied to a sodium bicarbonate dialysis agent,
Baking soda component as alkalizing agent (hereinafter referred to as agent B)
Is not particularly limited, and may be supplied as a concentrated solution or powder. When it is supplied in the form of powder, it is preferable that the agent B is also granulated because the fluidity is improved and dust generation can be suppressed.

【0019】A剤のブドウ糖の一部は、B剤に配合して
もよいが、この場合は、B剤が重曹とブドウ糖との混合
造粒物となる。しかし、ブドウ糖を配合したB剤は細菌
が増殖し昜いので注意が必要である
Part of the glucose of the agent A may be blended with the agent B. In this case, the agent B is a mixed granulation of baking soda and glucose. However, it is necessary to be careful because agent B containing glucose is prone to bacterial growth.

【0020】本発明は、酢酸透析用剤にも適用できる。
この場合、重曹透析用剤におけるA剤に、さらに酢酸ナ
トリウムを加えて粉体を得る。そして、上述の方法と同
様な方法で、水分量を制御することにより、黄色化を防
ぐことができる。
The present invention can also be applied to an acetic acid dialysis agent.
In this case, sodium acetate is further added to the agent A in the sodium bicarbonate dialysis agent to obtain a powder. Then, yellowing can be prevented by controlling the amount of water in the same manner as described above.

【0021】[0021]

【実施例】【Example】

(実施例1)それぞれ平均粒径50μm程度に粉砕された
塩化ナトリウム、塩化カリウム、塩化カルシウム2水和
物、塩化マグネシウム6水和物、酢酸ナトリウム無水物
及びブドウ糖を下記の比率で混合し、さらに乾燥基準で
1.5 重量%の水を添加して混合した。 NaCl 74.7110 重量% KCl 1.7943 〃 CaCl2・2H2O 2.2839 〃 MgCl2・6H2O 1.2408 〃 CH3COONa 7.9296 〃 ブドウ糖 12.0404 〃
(Example 1) Sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate anhydrous and glucose each crushed to an average particle size of about 50 μm were mixed in the following ratio, and further, On a dry basis
1.5 wt% water was added and mixed. NaCl 74.7110 wt% KCl 1.7943 〃 CaCl 2・ 2H 2 O 2.2839 〃 MgCl 2・ 6H 2 O 1.2408 〃 CH 3 COONa 7.9296 〃 Glucose 12.0404 〃

【0022】該当混合物をスクリーン径0.5 mmの押し出
し造粒機を用いて造粒し、直径0.5mm、長さ1〜10mmの
円柱状の粒子を100 kg得た。次に、相対湿度70%の空
気(室温)を用い、事前に相対湿度を50%まで脱湿した
空気を吹き込みつつ温度50℃に調整された回分式箱型乾
燥機に前記粒子を入れ3時間乾燥した。その後更に、氷
酢酸を1.5 重量%加えて、これをA剤とした。このA剤
は顆粒状であり、水銀圧入式ポロシメーターにより測定
した細孔容積は、0.08 cm3/gであった。
The mixture was granulated using an extrusion granulator having a screen diameter of 0.5 mm to obtain 100 kg of cylindrical particles having a diameter of 0.5 mm and a length of 1 to 10 mm. Next, using air (room temperature) with a relative humidity of 70%, the particles were put into a batch-type box dryer whose temperature was adjusted to 50 ° C. for 3 hours while blowing air dehumidified to a relative humidity of 50% in advance. Dried. Thereafter, 1.5% by weight of glacial acetic acid was further added, and this was used as the agent A. This agent A was granular and had a pore volume of 0.08 cm 3 / g as measured by a mercury porosimetry porosimeter.

【0023】このA剤について、日本薬局方のカールフ
ィッシャー法により水分を測定した。包装後に保管し、
黄色化の試験に供した。包装袋は30cm×40cmのアルミラ
ミネート袋とし外部よりの水分の透過を完全に防いだも
のとし、包装後ヒートシールし1年間室内にて常温で保
管した後に開封し、目視及び日本薬局方のブドウ糖注射
液中の5−ヒドロキシメチルフルフラール類の測定法に
て吸光度にて測定し黄色化程度とした。ここで吸光度値
が0.1 以下ならばほとんど白色であり全く商品価値を損
ねることは無く、0.2 以下であれば微黄色で実質的に問
題なく、0.3 程度が許容限度と考えられる。結果をそれ
ぞれ表1に示す。
The water content of this agent A was measured by the Karl Fischer method of the Japanese Pharmacopoeia. Store after packaging,
It was subjected to a yellowing test. The packaging bag shall be an aluminum laminate bag of 30 cm x 40 cm, which completely prevents the permeation of moisture from the outside. After packaging, heat seal it, store it at room temperature for 1 year at room temperature, then open it, and visually and glucose in the Japanese Pharmacopoeia. The degree of yellowing was determined by measuring the absorbance by the method for measuring 5-hydroxymethylfurfural in the injection solution. Here, if the absorbance value is 0.1 or less, it is almost white and does not impair the commercial value at all, and if it is 0.2 or less, it is slightly yellow and there is no problem, and about 0.3 is considered to be the allowable limit. The results are shown in Table 1.

【0024】(実施例2〜4)それぞれ実施例1と全く
同様な操作により粉砕、混合、及び造粒したA剤を温度
50℃に調整された回分式箱型乾燥機に入れ、乾燥時間を
表1に示したように変えてA剤中の水分の調整を行い、
その後更に、氷酢酸を1.5 重量%加えて、これを実施例
2〜4とした。
(Examples 2 to 4) The agent A crushed, mixed and granulated by the same procedure as in Example 1 was heated to the temperature.
Put in a batch type box dryer adjusted to 50 ° C, change the drying time as shown in Table 1 to adjust the water content in the agent A,
Thereafter, glacial acetic acid was further added in an amount of 1.5% by weight to give Examples 2 to 4.

【0025】(実施例5)実施例1と同様な操作により
粉砕及び混合しスクリーン径1.2mm の押し出し造粒機を
用いて造粒し、直径1.2mm 、長さ1 〜10mmの円柱状の粒
子を得、温度50℃に調整された回分式箱型乾燥機に入れ
3時間乾燥した。その後更に、氷酢酸を1.5 重量%加え
て、これを実施例5とした。
(Example 5) Pulverized and mixed by the same operation as in Example 1 and granulated using an extrusion granulator having a screen diameter of 1.2 mm, and cylindrical particles having a diameter of 1.2 mm and a length of 1 to 10 mm. And was placed in a batch-type box dryer whose temperature was adjusted to 50 ° C. and dried for 3 hours. After that, 1.5% by weight of glacial acetic acid was further added, and this was made to be Example 5.

【0026】(比較例)実施例1と同様な操作により粉
砕及び混合しスクリーン径1.2mm の押し出し造粒機を用
いて造粒し、直径1.2mm 、長さ1 〜10mmの円柱状の粒子
を得、相対湿度70%の空気(室温)を脱湿しないでそ
のまま乾燥機に導入した以外は同じ条件にして、50℃に
調整された回分式箱型乾燥機に入れ3時間乾燥した。そ
の後更に、氷酢酸を1.5 重量%加えて、これを比較例と
した。
(Comparative Example) Crushing and mixing were carried out in the same manner as in Example 1 and granulated using an extrusion granulator having a screen diameter of 1.2 mm to obtain cylindrical particles having a diameter of 1.2 mm and a length of 1 to 10 mm. Then, under the same conditions, the air (room temperature) having a relative humidity of 70% was introduced into the dryer as it was without being dehumidified, and the mixture was placed in a batch type box dryer adjusted to 50 ° C. and dried for 3 hours. Thereafter, 1.5% by weight of glacial acetic acid was further added, and this was used as a comparative example.

【0027】[0027]

【表1】 [Table 1]

【0028】[0028]

【発明の効果】本発明の透析用剤は水に溶解して均質な
水溶液になり簡単に透析液を得ることができ、ブドウ糖
の黄色化を防ぐことができるので商品の外観を損なうこ
となく長期の保管が可能である。また、本透析用剤は、
体積が小さくでき、貯留時に粉化したりあるいは難溶性
の化合物が生成したりせず保存あるいは輸送に有利であ
る。更に、流動性に優れているので、取扱いが容易であ
る。
EFFECT OF THE INVENTION The dialysis agent of the present invention dissolves in water to form a homogeneous aqueous solution, and a dialysis solution can be easily obtained, and the yellowing of glucose can be prevented. Can be stored. In addition, this dialysis agent
The volume can be made small, and it is advantageous for storage or transportation because it does not powder when stored or does not form a sparingly soluble compound. Furthermore, since it has excellent fluidity, it is easy to handle.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 固体の電解質及びブドウ糖成分を混合し
た透析用剤において、この混合物中のの水分が2.0 重量
%以下である透析用剤。
1. A dialysis agent in which a solid electrolyte and a glucose component are mixed, and the water content in the mixture is 2.0% by weight or less.
【請求項2】 アルカリ化剤として重曹を別に用いる請
求項1の透析用剤。
2. The dialysis agent according to claim 1, wherein baking soda is separately used as the alkalizing agent.
JP3107044A 1991-05-13 1991-05-13 Dialysis agent Pending JPH06105906A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3107044A JPH06105906A (en) 1991-05-13 1991-05-13 Dialysis agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3107044A JPH06105906A (en) 1991-05-13 1991-05-13 Dialysis agent

Publications (1)

Publication Number Publication Date
JPH06105906A true JPH06105906A (en) 1994-04-19

Family

ID=14449100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3107044A Pending JPH06105906A (en) 1991-05-13 1991-05-13 Dialysis agent

Country Status (1)

Country Link
JP (1) JPH06105906A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047488A1 (en) * 1997-04-24 1998-10-29 Fresenius Medical Care Deutschland Gmbh Method for the production of a granulate for hemodialysis
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
JP2016209485A (en) * 2015-05-13 2016-12-15 富田製薬株式会社 Granulated substance for dialysis a agent and preparation method thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047488A1 (en) * 1997-04-24 1998-10-29 Fresenius Medical Care Deutschland Gmbh Method for the production of a granulate for hemodialysis
US6210803B1 (en) 1997-04-24 2001-04-03 Fresenius Medical Care Deutschland Gmbh Method for the production of a granulate for hemodialysis
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US7758900B2 (en) 1999-04-26 2010-07-20 Baxter International Inc. Multi-part substitution infusion fluids and matching anticoagulants
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US8158157B2 (en) 1999-04-26 2012-04-17 Baxter International Inc. Multi-part substitution infusion fluids and matching anticoagulants
US8529486B2 (en) 1999-04-26 2013-09-10 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US8795517B2 (en) 1999-04-26 2014-08-05 Nikkiso Co., Ltd. Machine readable medium embodying instructions for citrate anticoagulation system for extracorporeal blood treatments
JP2016209485A (en) * 2015-05-13 2016-12-15 富田製薬株式会社 Granulated substance for dialysis a agent and preparation method thereof

Similar Documents

Publication Publication Date Title
EP0417478B2 (en) Sodium bicarbonate containing mixture for producing a dialysis solution
EP2151247B1 (en) Solid dialysis preparation
JP6366214B6 (en) Agent A for hemodialysis
JPH0116818B2 (en)
JP2749375B2 (en) Preparation for hemodialysis and method for producing the same
JP3433979B2 (en) Dialysis agent and method for producing the same
CN100558344C (en) Solid preparation for dialysis and method for producing same
EP1192960B1 (en) Solid preparation for dialysis and process for producing the same
JPH04257522A (en) Dialyzing agent for sodium bicarbonate
JPH0892070A (en) Blood dialyzing agent
JP2809971B2 (en) Hemodialysis preparation
JPH06105906A (en) Dialysis agent
JP4001062B2 (en) Solid dialysis agent and method for producing the same
JPH0892071A (en) Bicarbonate dialyzing agent
JPH11114054A (en) Solid dialysis agent
JP2986810B2 (en) Dialysis agent and method for producing the same
JP4561978B2 (en) Solid dialysis agent and method for producing the same
JP3714050B2 (en) Solid baking soda dialysis agent and method for producing the same
JP2986256B2 (en) Granules for hemodialysis
JP3076051B2 (en) Baking soda dialysis agent
JP6312957B1 (en) Agent A for hemodialysis
JP4385802B2 (en) Method for producing powder dialysis agent
JP4328851B2 (en) Bicarbonate solid dialysate
JP2751933B2 (en) Preparation for hemodialysis and method for producing the same
TWI772408B (en) Agent A for hemodialysis